Choose a language and wait for the translated text.
Shots:
MetaVia has reported interim P-I Part 3B data of once-weekly DA-1726 (GLP1R/GCGR dual agonist) in adults with obesity, showing a 68% PBO-adjusted liver-fat reduction (MRI-PDFF; GMR 0.32; p<0.001) & 13.5% PBO-adjusted weight loss at Day 109 (~16wks.)
In the MRI substudy (n=12 vs 4 PBO), 83% achieved ≥30% relative liver-fat reduction vs 0% on PBO; all 5 pts with baseline steatosis (MRI-PDFF ≥5%) fell below 5%; HbA1c fell from 5.79% to 5.33% (−0.24pp vs PBO; p=0.006)
No GI AEs led to discontinuation & no new GI AEs after Wk. 9 through Day 109; full Part 3A/3B data expected Q1’27, with a 48-wk. non-biopsy P-II in MetALD/ALD targeted for H2’27
Ref: MetaVia | Image: MetaVia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post MetaVia Reports P-I Part 3B Interim Data of DA-1726 Showing 68% Placebo-Adjusted Liver Fat Reduction appeared first on PharmaShots.
